Harrow Health. has filed a patent for a pharmaceutical composition that includes glycopeptide and aminoglycoside antibiotics, along with amino acids. The composition is intended for ophthalmic use and is formulated with a pharmaceutically acceptable aqueous carrier. Methods for manufacturing and using the composition are also described. GlobalData’s report on Harrow Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Harrow Health, Peptide pharmacophores was a key innovation area identified from patents. Harrow Health's grant share as of September 2023 was 27%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230302032A1) describes an ophthalmic pharmaceutical composition for treating ophthalmological diseases, conditions, disorders, syndromes, or pathologies in mammals. The composition includes at least one antibiotic selected from glycopeptide antibiotics and aminoglycoside antibiotics, at least one amino acid, and a pharmaceutically acceptable aqueous carrier.
The glycopeptide antibiotic can be vancomycin, decaplanin, ramoplanin, cefuroxime, teicoplanin, telavancin, corbomycin, complestatin, or any combination thereof. The aminoglycoside antibiotic can be tobramycin, kanamycin A, amikacin, dibekacin, gentamicin, sisomicin, netilmicin, neomycin B, neomycin C, paromomycin, plazomicin, streptomycin, or any combination thereof.
The composition may also include a therapeutically effective quantity of at least one anesthetic compound, such as lidocaine, tetracaine, proparacaine, procaine, dyclonine, chloroprocaine, or any combination thereof. The concentration of the anesthetic compound in the composition can range from about 0.25 mass % to about 5.0 mass %, with a concentration of about 1.0 mass % being preferred.
The concentration of glycopeptide antibiotics in the composition can range from about 1.0 mass % to about 10.0 mass %, while the concentration of aminoglycoside antibiotics can range from about 1.0 mass % to about 5.0 mass %. The composition has a pH between about 4.0 and about 6.0, with a preferred pH range of about 5.1 to about 5.3.
The composition also includes at least one amino acid, such as L-glycine, L-cysteine, L-lysine, N-acetyl-D-alanine, or any combination thereof. The concentration of the amino acid in the composition can range from about 0.1 mass % to about 1.5 mass %. For example, L-glycine can have a concentration of between about 0.1 mass % to about 1.0 mass %, L-cysteine can have a concentration of between about 0.1 mass % to about 0.2 mass %, L-lysine can have a concentration of between about 0.1 mass % to about 1.0 mass %, and N-acetyl-L-alanine can have a concentration of between about 0.25 mass % to about 1.5 mass %.
The ophthalmic pharmaceutical composition is stable for at least 30 days when refrigerated and remains potent for at least 30 days when refrigerated.
In summary, this patent describes an ophthalmic pharmaceutical composition that includes antibiotics, amino acids, and an aqueous carrier. The composition can be used to treat various ophthalmological diseases, conditions, disorders, syndromes, or pathologies in mammals. The composition is stable and potent when refrigerated for extended periods of time.
To know more about GlobalData’s detailed insights on Harrow Health, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
